1Casciato DA, Chansky HA. Bone and joint complications [C]. In: Casiato DA, Lowitz BB, eds Manual of Clinical Oncology. 4thed. Philadelphia, PA: Lippincott Williams Wilkins, 2000: 601-614
2Robinson RG, Preston DF, Schiefelbein M,et al. Strontium89 therapy for the palliation of pain due to osseous metastases[J].JAMA, 1995 ,274(5):420
3Crawford ED, Kozlowski JM, Debruyne FM,et al. The use of strontium89 for palliation of pain from bone metastases associated with hormone refractory prostate cancer[J]. Urology, 1994, 44(4): 481
4Sciuto R, Festa A, Pasqualoni R, et al. Metastases bone pain palliation with 89-Sr and 186-ReHEDP in breast cancer patients [J]. Breast Cancer Res Treat, 2001,66(2) : 101-109
5Falkmer U, Jarhult J, Wersall P, et al. A systematic overview of radiation therapy effects in skeletal metastases [J]. Acta Oncol, 2003,42(5-6) :620-633
6Sciuto R, Festa A, Pasqualoni R, et al. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients[J]. Br Cancer Res Treat, 2001,66: 101-109
7Graham MC, Scher HI, Liu GB, et al. Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen independent prostate cancer [J].Clin Cancer Res, 1999,5:1307-1318
8Palmedo H, Guhlke S, Bender H, et al. Dose escalation study with rhenium-188 hydroxye thylidene diphosphonate in prostate cancer patients with osseous metastases [J].Eur J Nucl Med,2000,27:123-130
9Palmedo H, Manka-Waluch A, Albers P, et al. Repeated bone-targeted therapy for hormone refractory prostate carcinoma: randomized phase Ⅱ trial with the new,high-energy- radiophar maceutieal rhenium-188 hydroxyethylidenediphos- phonate[J].J Clin Oncol, 2003,21:2869-2875
10Dafermou A, Colamussi P, Giganti M, et al. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer [J]. EurJ Nucl Med, 2001,28:788-798
